News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
華潤醫藥(03320.HK)旗下1,4-丁二胺導入下游客戶新品體系
華潤醫藥(03320.HK)公布，集團旗下華潤雙鶴所屬業務單元神舟生物，於合成生物產業化應用領域迎來重要突破，核心生物基產品1,4 - 丁二胺已成功導入下游合作夥伴沃特股份全新發布的Wouper PA46 生物基高性能聚醯胺材料體系，標誌集團相關產品正式進入高性能材料終端應用領域。沃特股份推出之Wouper PA46，定位為生物基高性能聚醯胺標杆產品。該材料...
Reset
Send
The window will close in 5 seconds
華潤醫藥(03320.HK)旗下1,4-丁二胺導入下游客戶新品體系
Close
Recommend
2
Positive
0
Negative
3
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

華潤醫藥(03320.HK)  -0.110 (-1.792%)    Short selling $65.09M; Ratio 42.540%   公布，集團旗下華潤雙鶴所屬業務單元神舟生物，於合成生物產業化應用領域迎來重要突破，核心生物基產品1,4 - 丁二胺已成功導入下游合作夥伴沃特股份全新發布的Wouper PA46 生物基高性能聚醯胺材料體系，標誌集團相關產品正式進入高性能材料終端應用領域。

沃特股份推出之Wouper PA46，定位為生物基高性能聚醯胺標杆產品。該材料融合生物基原料的綠色屬性與高性能工程塑料的嚴苛工況要求，具備高強度、低蠕變、耐疲勞、寬溫域耐磨、自潤滑、高流動性、耐焊接、耐油抗水解等多項優異性能，可廣泛應用於汽車傳動系統、精密電子及電氣工業等高端製造領域，展現強勁的下游應用潛力。(ha/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-22 16:25.)

AASTOCKS新聞

Switch to Auto-Translated Version
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.